Patents Assigned to SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
  • Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
    Patent number: 11639355
    Abstract: Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: May 2, 2023
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Xiaobing Yan, Jianglei Huang, Yuekun Nie, Guoping Hu, Jian Li, Shuhui Chen, Jiaqiang Dong, Tie-Lin Wang
  • Crystal form of estrogen receptor inhibitor and preparation method therefor
    Patent number: 11034653
    Abstract: Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 15, 2021
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Huijun He, Jianyu Lu, Weidong Li, Shenyi Shi, Zhijuan Chen, Charles Z. Ding, Lihong Hu, Tie-Lin Wang, Jiaqiang Dong
  • Indolo substituted piperidine compound as estrogen receptor down-regulator
    Patent number: 10774081
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: September 15, 2020
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Xu Zeng, Huijun He, Shuhui Chen, Lihong Hu, Jiaqiang Dong, Tie-Lin Wang
  • INDOLO SUBSTITUTED PIPERIDINE COMPOUND AS ESTROGEN RECEPTOR DEGRADING AGENT
    Publication number: 20190337938
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor degrading agent. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor degrading agent in the treatment of estrogen receptor positive breast cancers.
    Type: Application
    Filed: October 30, 2017
    Publication date: November 7, 2019
    Applicants: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu LU, Charles Z. DING, Xu ZENG, Huijun HE, Shuhui CHEN, Lihong HU, Jiaqiang DONG, Tie-Lin WANG
  • Process of synthesizing substituted pyridine and pyrimidine compound
    Patent number: 10316033
    Abstract: Provided is a process of synthesizing a substituted pyridine and pyrimidine compound. Particularly, provided is a method for preparing a compound of formula III via a compound of formula II?, wherein the definition of each of groups is as described as the description. Compound with other methods, the method in the present invention has features of high yield and a result product being easier to separate.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 11, 2019
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
    Inventors: Jingkang Shen, Tao Meng, Ting Yu, Lanping Ma, Xin Wang, Lin Chen
  • Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof
    Patent number: 9796732
    Abstract: The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: October 24, 2017
    Assignee: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jingkang Shen, Ke Yu, Tao Meng, Lanping Ma, Arie Zask, Lanfang Meng, Xin Wang, Yiyi Chen